Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe ...

One of Merck KGaA’s leading immunology assets has flunked the latest part of a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded further development is warranted in ...

A new study of more than 2,900 patients provides evidence that it's likely best to use as little corticosteroid medicine as ...

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other ...

Pericarditis recurrence in lupus is more likely — and has a dose-dependent relationship — with oral prednisone treatment, ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Peter M.

Rheumatoid arthritis (RA) and lupus both cause joint pain and stiffness. Despite some similarities, it’s easy for doctors to distinguish them. RA has more debilitating effects on the joints.

Pericarditis recurrence in lupus is more likely — and has a dose-dependent relationship — with oral prednisone treatment, though overall it is lower than in the general population, according ...

Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many ...

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...